Compared side by side

KPV vs LL-37: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

KPV is three amino acids from the tail end of α-MSH; in cell and mouse studies it enters cells and blocks NF-κB, the master switch for inflammatory signals. LL-37 is the body’s own antimicrobial peptide: in lab studies it kills bacteria, fungi and some viruses and steers immune responses, and it can be anti- or pro-inflammatory depending on context. No human study has tested KPV, and LL-37 has been tested as a drug only as a topical treatment for leg and foot ulcers.

Side by side

ComparedKPVLL-37
CategoryHealing & recoveryHealing & recovery
Also known asLys-Pro-Val, α-MSH tripeptideCathelicidin, hCAP-18, CAP-18
What it isOne of the smallest bioactive peptides: three amino acids from the tail end of α-MSH.Your body's own antimicrobial peptide.
How it worksC-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans.Human antimicrobial peptide with broad-spectrum antimicrobial activity. In lab and animal studies it modulates innate immunity, breaks up biofilms and promotes wound healing; it can be anti- or pro-inflammatory depending on context.
Commonly reportedA calmer gut and calmer skin. No human study has tested it yet.Noticeable injection-site redness or itching, and for some a flu-like, achy feeling in the first days. As a drug it has only been tested as a topical treatment for leg and foot ulcers, with mixed results; injected LL-37 hasn't been studied in people.
Studied rangeResearch range: 100–300 mcg. Studied in research — not a recommendation.Research range: 100–300 mcg. Studied in research — not a recommendation.
How oftenDailyDaily or EOD
Half-lifeNot measured: no half-life for KPV has been published, in people or animalsUnknown in humans (short; broken down by proteases)
RouteSubQ injection, OralSubQ injection
Typical run4–8 weeks typical for gut protocols. Can reassess after each cycle.Short cycles of 2–4 weeks due to limited data. Conservative approach advised.
EvidenceEmerging: primarily preclinical / limited human dataEmerging: primarily preclinical / limited human data
Common side effectsInjection site irritation, mild nauseaInjection site pain, redness, mild systemic inflammation

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Taking KPV or LL-37? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

KPV

  • Day 1–7 Week one: your starting point
  • Day 7–21 Users often report a calmer gut
  • Day 21–42 Some report calmer skin
  • Day 42–56 Weeks 6 to 8: taking stock

Every card for KPV, with its sources

LL-37

  • Day 1–7 Some feel a flu-like wave early
  • Day 7–21 Weeks 1 to 3: check what changed
  • Day 21–28 Cycle wrap-up — time to assess

Every card for LL-37, with its sources

Together or one or the other

KPV and LL-37 are a common stack: each lists the other among its common stacks.

Community · LL-37

An immune-support trio

Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.

Questions people ask

How long do KPV and LL-37 last?

The half-life of KPV is not measured: no half-life for KPV has been published, in people or animals. The half-life of LL-37 is unknown in humans (short; broken down by proteases).

How often are KPV and LL-37 taken?

KPV: daily. Routes: SubQ injection, oral. LL-37: daily or EOD. Route: SubQ injection.

How are KPV and LL-37 dosed in research?

The research range for KPV is 100–300 mcg. The research range for LL-37 is 100–300 mcg. Studied in research — not a recommendation.

What are the common side effects of KPV and LL-37?

For KPV, the library lists: injection site irritation, mild nausea. For LL-37: injection site pain, redness, mild systemic inflammation.

Are KPV and LL-37 taken together?

KPV and LL-37 are a common stack: each lists the other among its common stacks. Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.

Each one in full

Track it in the app

PepVault for iPhone

Taking KPV or LL-37? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo